Inocras Raises 46.5 Billion Won in Funding, Targets U.S. Cancer Diagnostics Market

Inocras, a cancer genomics big data company, secured $31 million (approximately 46.5 billion won) in a Series B-3 financing, bringing its cumulative funding to $100 million. The company provides cancer diagnostic and treatment information based on whole-genome data analysis technology and plans to use the funds to expand into the U.S. hospital market. Building on its precision diagnostic solutions CancerVision and MRDvision, which are already supplied to more than 100 medical institutions in Asia, the company plans to significantly expand its commercial and operational infrastructure in the United States.